Differences

This shows you the differences between two versions of the page.

--- soren_gantt [2022/04/17 08:30]
liam [COVID-19]
+++ soren_gantt [2022/04/18 01:52] (current)
liam [Affiliations]
@@ Line 16: / Line 16: @@
 Gantt is employed as a research and professor by the [[University of Montreal]].((Université de Montréal. //Soren Gantt.// Département de Microbiologie, Infectiologie et Immunologie. Retrieved April 16, 2022, from https://web.archive.org/web/20220417050458/https://microbiologie.umontreal.ca/recherche/professeurs-chercheurs/soren-gantt/)) He is a Pediatric Infectious Diseases specialist and director of clinical research at [[CHU Sainte-Justine Research Center]].((//Biography.// (2020). CHU Sainte-Justine Research Center. https://web.archive.org/web/20210603074958/https://www.chusj.org/Bio?id=b3e2368d-ae9a-4f08-a8c3-c694adbb0bda&lang=en)) He serves as CHU Sainte-Justine's investigator for the [[MUHC Vaccine Study Centre]] alongside [[Caroline Quach-Trahn.]]((//About.// MUHC Vaccine Center. Retrieved March 21, 2022, from https://archive.ph/MX0cf))
 ===== COVID-19 =====
-Gantt served as a member of Canada's [[National Advisory Committee on Immunization]] (NACI) when [[COVID-19 vaccines]] were first approved in Canada. He later declared receiving funding from [[pharmaceutical_companies:Pfizer]] and [[pharmaceutical_companies:Moderna]], whose vaccines he helped approve. He reported additional funding from [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:GlaxoSmithKline]] and [[medical_technology_companies:Altona Diagnostics]].((Byrne, C., Coombs, D., & Gantt, S. (2022). //Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level.// medRxiv. Preprint. https://doi.org/10.1101/2022.03.24.22272898))
+Gantt served as a member of Canada's [[National Advisory Committee on Immunization]] (NACI) when [[COVID-19 vaccines]] were first approved in Canada. He later declared receiving funding from [[pharmaceutical_companies:Pfizer]] and [[pharmaceutical_companies:Moderna]], whose vaccines he helped approve. Shockingly, he further discloses that he received funding for a Moderna COVID-19 vaccine trial, investigating its use in babies.((//Montreal clinical trial to vaccinate babies with COVID-19 shot.// (2021, December 3). City News Montreal. https://web.archive.org/web/20220417174636/https://montreal.citynews.ca/video/2021/12/03/montreal-clinical-trial-to-vaccinate-babies-with-covid-19-shot/)) ((Sherwin, C. (2021, November 26). //Babies and toddlers are getting COVID-19 vaccines in Montreal as part of a clinical trial.// CTV News. https://archive.ph/u08Zc)) ((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343)) He reported additional funding from [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:GlaxoSmithKline]] and [[medical_technology_companies:Altona Diagnostics]].((Byrne, C., Coombs, D., & Gantt, S. (2022). //Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level.// medRxiv. Preprint. https://doi.org/10.1101/2022.03.24.22272898))
+In a paper published in the [[Canadian Medical Association Journal]], Gantt describes receiving consulting fees related to vaccines from Moderna, GlaxoSmithKline, Merck and [[pharmaceutical_companies:Curevo Vaccine]]; research funding for vaccine research from Merck, GlaxoSmithKline and [[pharmaceutical_companies:VBI Vaccines]]; and research funding for a COVID-19 vaccine trial from [[pharmaceutical_companies:Symvivo]].((Abu-Raya, B., Gantt, S., & Sadarangani, M. (2020). //Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.// Canadian Medical Association Journal, cmaj.201237. https://doi.org/10.1503/cmaj.201237))